Krystal Biotech Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M |
| SG&A Expense | $146.7M | $113.6M | $98.3M | $77.7M | $40.4M |
| Operating Income | $161.3M | $65.7M | $-109.6M | $-145.2M | $-68.3M |
| Operating Margin | 41.5% | 22.6% | -216.2% | — | — |
| Interest Expense | — | — | $0 | $0 | $1.5M |
| Pretax Income | $189.5M | $95.4M | $12.9M | $-140.0M | $-69.6M |
| Income Tax Expense | $-15.4M | $6.2M | $2.0M | $0 | $0 |
| Net Income | $204.8M | $89.2M | $10.9M | $-140.0M | $-69.6M |
| Net Margin | 52.6% | 30.7% | 21.6% | — | — |
| EPS (Basic) | $7.08 | $3.12 | $0.40 | $-5.49 | $-3.13 |
| EPS (Diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
| Shares Outstanding (Basic) | 28.9M | 28.6M | 27.2M | 25.5M | 22.2M |
| Shares Outstanding (Diluted) | 30.0M | 29.7M | 27.8M | 25.5M | 22.2M |
| Dividends Per Share | — | — | — | — | — |